A nthrax probably caused the ''festering boils'' of the people and cattle of Egypt described in the sixth plague of the Old Testament. After the discovery of Bacillus anthracis by Robert Koch in 1880 (1), Pasteur (2) developed a vaccine for sheep composed of chemically treated attenuated strains. Routine use of a noncapsulated strain has virtually eliminated anthrax among domesticated animals (3) . In the only controlled study of an anthrax vaccine in humans, culture-supernatant from a capϪ nonproteolytic strain that produced protective antigen (PA), conferred 92% efficacy among woolsorters (4) . The Centers for Disease Control monitored the anthrax vaccine adsorbed (AVA) in industrial settings between 1962 and 1974: none of 34 cases occurred in fully vaccinated individuals. A similar vaccine is used in the U.K. (5) . This and other evidence indicate that serum IgG anti-PA confers immunity to cutaneous and inhalational anthrax in humans (6, 7) .
The structure and expression of the essential virulence factors of B. anthracis are controlled by two plasmids. pX01 encodes anthrax toxin (AT) composed of the PA (binding subunit of AT), and two enzymes known as lethal factor and edema factor (8, 9) . Administration of AT to primates mimics the symptoms of anthrax (9) . pX02 encodes the poly(␥-D-glutamic acid) (␥DPGA) capsule of B. anthracis (10, 11) . Other bacilli produce poly(␥-glutamic acid) (␥PGA) but only B. anthracis synthesizes it entirely in the D conformation (12) . ␥DPGA is a surface structure (13) , inhibits in vitro phagocytosis and, when injected, is a poor immunogen even as a bacterial component (14) (15) (16) (17) (18) ; the protective effect of anti-␥DPGA has not been reported. The capsule shields the vegetative form of B. anthracis from agglutination by monoclonal antibodies to its cell wall polysaccharide (19) . Systemic infection with B. anthracis induces ␥DPGA antibodies (20) . Antibodies to D-amino acid polymers may be induced in animals by injection of ␥DPGA methylated BSA complexes along with Freund's adjuvant, i.v. injections of a formalin-treated capsulated B. anthracis, or by peptidyl proteins (16, 21) . We report the synthesis and evaluation of conjugates that induce ␥DPGA antibodies under conditions suitable for clinical use.
Experimental Procedures
Bacterial Strains. Bacillus pumilus strain Sh18 and B. anthracis strain A34, a pX01Ϫ, pX0 2ϩ variant derived from the Ames strain by repeated passage at 43°C, have been described (10, 22) . in 1:1 CH 3 CN and 0.1% trifluroacetic acid) was dried on the sample stage. Second, 1 l of sample and an additional 1 l of matrix were applied. After the ''sandwich'' was dried, the sample was placed in the mass spectrometer.
Antigens. BSA (Sigma) was dialyzed against pyrogen-free water, sterile-filtered, and freeze-dried. Recombinant PA (rPA) from B. anthracis and recombinant exoprotein A (rEPA) from Pseudomonas aeruginosa were prepared and characterized (29, 30) .
␥PGA was extracted from the culture supernatant of B. anthracis or B. pumilus by cetavlon precipitation, acidification to pH 1.5, precipitation with ethanol, and passage through a 2.5 ϫ 100-cm Sepharose CL-4B column in 0.2 M NaCl (23) . Their compositions were confirmed by 1 H-NMR and 13 C-NMR, and their enantiomeric conformations were compared by GLC-MS spectroscopy.
Three types of ␥PGA peptides (AnaSpec, San Jose, CA) were synthesized by the method of Merrifield with 5, 10, or 20 residues. Their purity and authenticity were verified by GLC-MS, liquid chromatography MS, and MALDI-TOF. The peptides were bound to the protein at the C or the N termini (-C indicates that the C terminus is free, and N-indicates that the amino terminus is free).
Y Type I, NBrAc-Gly 3 -␥DPGA n -COOH(Br-Gly 3 -␥DPGA n -C);
NBrAc-Gly 3 -␥LPGA n -COOH(Br-Gly 3 -␥LPGA n -C).
Y Type III, NAc-␥DPGA n -Gly 3 -L-Cys-CONH 2 (N-␥DPGA n -Gly 3 -Cys); NAc-␥LPGA n -Gly 3 -L-Cys-CONH 2 (N-␥LPGA n -Gly 3 -Cys).
Conjugations to rPA are described. BSA and rEPA were used in a similar manner. All reactions were conducted in a pH stat under argon.
Conjugation of rPA with B. anthracis ␥DPGA and with B. pumilus ␥DLPGA. rPA was derivatized with adipic acid dihydrazide with modifications (28) . The pH was maintained at 7.0, and 0.1 M 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide⅐HCl (EDAC) was used. The product, rPA-AH, contained 2.0-4.7% hydrazide. ␥PGA was bound to rPA-AH or rEPA-AH with 0.01 M EDAC, the reaction mixture was passed through a 1 ϫ 90-cm Sephacryl S-1000 column in 0.2 M NaCl, and fractions reacting with anti-PA and anti-␥DPGA by an identity line were pooled. Step 1 consisted of derivatization of rPA with N-hydroxysuccinimide ester of 3-(2-pyridyl dithio)-propionic acid (SPDP). To rPA (30 mg) in 1.5 ml of buffer AЈ (PBS͞3% glycerol͞0.005 M EDTA, pH 7.6) , SPDP (10 mg) in 50 l of dimethyl sulfoxide was added in 10-l aliquots and reacted for 1 h at pH 7.6. The product, 2-pyridyldithio-propionyl-rPA (PDP-rPA), was passed through a 1 ϫ 48-cm Sephadex G-50 column in buffer A (PBS͞0.05% glycerol͞0.005 M EDTA, pH 7.6), and proteincontaining fractions were pooled and assayed for thiolation, antigenicity, and molecular mass (27) .
Step 2.
Step 2 consisted of conjugation of PDP-protein with type-I peptide. PDP-protein (24 mg) in 2 ml of buffer A was treated with 50 mM dithiotreitol for 30 min at room temperature and passed through a 1 ϫ 48-cm Sephadex G-50 column in buffer A. Fractions containing the 3-thiopropionyl--Lys-NH 2 -rPA (rPA-SH) were collected and concentrated to 1.5 ml, and glycerol was added to a final concentration of 3%. Br-Gly 3 -␥-DPGA n -C, 10 mg in 1 ml of buffer A, was adjusted to pH 7.6 with 1 M NaOH, and rPA-SH was added, incubated for 1 h at room temperature (31), transferred to a vial, capped, and tumbled overnight at room temperature. Bromoacetamide, 0.5 mg in 50 l of buffer A, was added to block unreacted thiols. After 30 min, the reaction mixture was passed through a 1 ϫ 90-cm Sephacryl S-200 column in buffer B (0.01 M phosphate͞0.2 M NaCl͞0.05% glycerol, pH 7.2). Fractions containing protein-PGA were polled and assayed for peptide and protein concentration, antigenicity, and molecular mass. Products. BSA contains 60, rPA contains 58, and rEPA contains 15 mol of Lys per mol of protein, respectively. Under the above conditions, 28 of 60 -Lys-NH 2 of BSA, 50-55 of 58 of rPA and 15 of 15 of rEPA were derivatized with N-hydroxysuccinimide ester of 3-(2-pyridyl dithio)-propionic acid with retention of their antigenicity. Conjugation of BSA-SH, rPA-SH and rEPA-SH with type-I peptides yielded: BSA-SH͞Gly 3 -␥DPGA n -C; BSASH͞Gly 3 -␥LPGA n -C; rEPA-SH͞Gly 3 -␥DPGA n -C; rPA-SH͞ Gly 3 -␥DPGA n -C.
Conjugation with Type-II and -III Peptides. Step 1. Derivatization of protein with succinimidyl 3-(bromoacetamido) propionate (SBAP). rPA (30 mg) in 1.5 ml of buffer AЈ was adjusted to pH 7.2. SBAP, 11 mg in 50 l dimethyl sulfoxide, was added in 10 l aliquots (31) . After 60 min, the reaction mixture was passed through a 1 ϫ 90-cm Sepharose CL-6B column in buffer B. Fractions containing bromoacetamidopropionyl--Lys-NH-rPA (Br-rPA) were collected and assayed for protein, free -NH 2 , antigenicity, and molecular mass.
Step 2 involved conjugation of Br-protein with type-II and -III peptides. Type-II or -III peptides (5-15 mg in 1 ml buffer A) were adjusted to pH 7.6 with 1 M NaOH and Br-protein (25 mg) in 1.5 ml buffer AЈ was added. After 1 h, the reaction mixture transferred to a vial, capped, and tumbled overnight at room temperature. 2-Mercaptoethanol (1 l) was added to quench the remaining bromoacetyl groups in Br-protein. After 30 min, the reaction mixture was passed through a 1 ϫ 90-cm Sepharose CL-6B column in buffer B. Fractions containing protein-PGA were polled and assayed for peptide and protein concentration, antigenicity, and molecular mass. Products. Under these conditions, 50-55 of 58 and 15 of 15 residues of -Lys-NH 2 of rPA and rEPA, respectively, were modified with succinimidyl 3-(bromoacetamido) propionate. Conjugation of Br-rPA and Br-rEPA with type-II peptides yielded four conjugates:
Conjugation of Br-rPA and Br-rEPA and with type-III peptides yielded four conjugates:
All eight conjugates precipitated with an identity reaction with their protein and ␥PGA antisera by immunodiffusion. Representative analysis by MALDI-TOF is shown in Fig. 2 .
Immunization. Five-to six-week-old female National Institutes of Health Swiss-Webster mice were immunized s.c. three times at 2-week intervals with 2.5 g of PGA as a conjugate in 0.1 ml of PBS, and groups of 10 mice were exsanguinated 7 days after the second or third injections (28) . Controls received PBS.
Antibodies. Serum IgG antibodies were measured by ELISA (32) . Nunc Maxisorb plates were coated with ␥DPGA, 20 g͞ml PBS, or 4 g of rPA per ml of PBS (determined by checkerboard titration). Plates were blocked with 0.5% BSA (or with 0.5% HSA for assay of BSA conjugates) in PBS for 2 h at room temperature. A MRX Dynatech reader was used. Antibody levels were calculated relative to standard sera: for ␥DPGA, a hyperimmune murine serum prepared by multiple i.p. injections of formalin-treated B. anthracis strain A34 and assigned a value of 100 ELISA units; for PA, a mAb containing 4.7 mg of Ab per ml (33) . Results were computed with an ELISA data processing program provided by the Biostatistics and Information Management Branch, Centers for Disease Control (34) . IgG levels are expressed as geometric mean (GM).
Opsonophagocytosis. Spores of B. anthracis strain A34 were maintained at 5 ϫ 10 8 spores per ml in 1% phenol. The human cell line HL-60 (CCL240, American Type Culture Collection) was expanded and differentiated by dimethyl formamide into 44% myelocytes and metamyelocytes and 53% band and polymorphonuclear leukocytes (PMN). PMN were at an effector͞ target cell ratio of 400:1. PMN were centrifuged and resuspended in opsonophagocytosis buffer (Hanks' buffer with Ca 2ϩ , Mg 2ϩ , and 0.1% gelatin; Life Technologies, Grand Island, NY) to 2 ϫ 10 7 . Spores were cultivated at 5 ϫ 10 7 per ml for 3 h, 20% CO 2 , and diluted to 5 ϫ 10 4 per ml. Sera were diluted 2-fold with 0.05 ml in opsonophagocytosis buffer in 24-well tissue culture plates (Falcon) and 0.02 ml containing Ϸ10 3 bacteria added to each well. The plates were incubated at 37°C, 5% CO 2 for 15 min. A 0.01-ml aliquot of colostrum-deprived baby calf serum (used as a complement) and 0.02 ml of HL-60 suspension containing 4 ϫ 10 5 cells was added to each well and incubated at 37°C for 45 min, 5% CO 2 , with mixing at 220 rpm in a Minitron incubator shaker (Infors AG, Bottmingen, Switzerland). A 0.01-ml aliquot from each well was added to tryptic soy agar (Difco) at 50°C, and colony-forming units were determined the next morning. Opsonophagocytosis was defined by Ն50% killing compared with the growth in control wells (35) .
Statistics. ELISA values are expressed as the GM. An unpaired t test was used to compare GMs in different groups of mice.
Results
Characterization of ␥PGA Conjugates. The PGA͞protein ratio was assessed by MALDI-TOF spectrometry that provided molecular mass of the conjugates and by GLC-MS that provided the amount of bound PGA ( Fig. 1 and 2 ). The two methods corroborated each other.
Serum IgG Anti-␥DPGA. Native ␥DPGA from the capsule of B. anthracis elicited trace levels of antibodies after the third injection. All of the conjugates, in contrast, elicited IgG anti-␥DPGA after two injections ( Table 1) . Conjugates of B. anthracis ␥DPGA and of B. pumilus ␥D(60%)L(40%)PGA elicited IgG anti-␥DPGA of intermediate levels after two injections with a booster after the third. Precipitates were formed during the synthesis of both conjugates resulting in low yields.
IgG anti-␥DPGA levels induced by the different conjugates overlapped. The highest levels were achieved with peptide decamers, 16 mol per protein for rPA͞Cys-Gly 3 -␥DPGA 10 -C, 11 and 14 mol per protein for rPA-SH͞Gly 3 -␥DPGA 10 -C. rPA was a more effective carrier than rEPA or BSA. With the exception of rPA-SH͞Gly 3 -␥DPGA 10 -C, with 11 chains per protein, all conjugates elicited a rise (mostly nonsignificant) after the third injection. Conjugates prepared with L peptides bound at either the C or N terminus induced low levels of IgG anti-␥DPGA. Table 2 shows the dose-response of two ␥DPGA conjugates with rPA or rEPA as the carrier; both peptides had 20 residues and similar numbers of chains per protein. Again, rPA was a NA, not applicable; ND, not done. *␥DPGA from B. anthracis, strain A34, 2.5 g as a conjugate used for injection, antibodies by ELISA expressed as EU. † Antibodies by ELISA expressed as g Ab͞ml. ‡ C or N refers to the free amino acid on the ␥PGA bound to the protein. Five-to six-week-old National Institutes of Health Swiss-Webster mice (n ϭ 10) injected s.c. with 0.1 ml of the conjugates every 2 weeks apart and exsanguinated 7 days after the third injection. IgG anti-␥DPGA was measured by ELISA, and the results are expressed as the GM (9,152 vs. 3,487, P ϭ 0.003; 9,152 vs. 4,901, P ϭ 0.04; 9,152 vs. 1,956, P Ͻ 0.0001; 7,070 vs. 2,393, P Ͻ 0.0001).
more effective carrier than rEPA. The lowest dose (2.5 g) of rPA-SH͞Gly 3 -␥DPGA-C elicited the highest level of IgG anti-␥DPGA (9,152 ELISA units), the levels declined Ϸ1͞2 at the 20-g dose. rEPA-SH͞Gly 3 -␥DPGA-C, in contrast, elicited similar levels at all dosages.
Serum IgG Anti-Carrier Protein. With a few exceptions, both the length and number of ␥DPGA chains per protein were related to the level of IgG antiprotein. Conjugates prepared with ␥DPGA containing 20 residues elicited low levels of protein antibodies, although in one case the induced GM level was the highest. In general, conjugates prepared with 5 or 10 residues and with Յ15 chains per protein elicited the highest levels of IgG protein antibodies.
Opsonophagocytic Activity of Mouse Antisera. Sera from normal mice or those immunized with rEPA or rPA did not have opsonophagocytic activity (not shown). Table 3 shows a rough correlation between the level of IgG anti-␥DPGA and opsonophagocytosis in mice immunized with BSA-SH͞Gly 3 -␥DPGA 10 -C or BSA-SH͞Gly 3 -␥DPGA 10 -C (r ϭ 0.7, P ϭ 0.03). Addition of ␥DPGA from B. anthracis to the immune sera showed a doserelated reduction of the opsonophagocytic titer of Ϸ60% (not shown).
Discussion
Worldwide control of anthrax has been achieved in most countries by education, immunization of domesticated animals with attenuated (noncapsulated) strains of B. anthracis, and immunization of at-risk individuals with PA (AVA) and with antibiotics. Deliberate contamination of the mail with B. anthracis spores prompted improvement of AVA because (i) consistency of production is difficult because there is no measurement of PA or of other components in the vaccine that cause local and systemic reactions; these problems should be solved by replacing AVA with a purified PA: (ii) administration of AVA by s.c. injections at 0, 2, and 4 weeks and 6, 12, and 18 months with yearly boosters was designed for rapid induction of immunity in at-risk individuals (36). Replacement of this schedule with that used for primary immunization with DTP will require only three injections 2 months apart for the primary series, and a booster at 1 year will yield higher levels of anti-PA (37) . (iii) The safety, immunogenicity, and efficacy of AVA in children have not been characterized.
The level of antibodies to PA required to confer immunity to B. anthracis seems high and may be difficult to maintain. Addition of anti-␥DPGA-induced opsonophagocytic killing could augment protection mediated by anti-PA against the high levels of spores that might occur during a bioterrorist attack.
␥DPGA and polysaccharides share some properties: (i) both are multivalent; (ii) both resist host enzyme catalysis; (iii) a hexamer of either occupies the antibody-combining site (38) ; (iv) covalent binding to a protein confers enhanced immunogenicity and T cell dependence (39) (40) (41) (42) ; and (v) conjugates of synthetic saccharides as well as of ␥DPGA elicited higher levels of antibodies than did the ''natural'' polymer (39) .
The structure determines the optimal immunogenicity for conjugates composed of linear polymers (hapten) bound at one point to a protein (39) (40) (41) (42) : (i) the hapten lengths should be sufficient to occupy the antibody combining site; and (ii) a critical density of the hapten on the carrier protein is necessary to form both aggregates with the surface Ig receptor and to permit interaction of the protein carrier fragments with T cells. As with synthetic oligosaccharides of Shigella dysenteriae type 1 (39), the results presented here and additional data not shown suggest that a decamer of ␥DPGA, bound to the protein at a density of 10-15 per mol of protein, would provide maximal immunogenicity.
Similar to the surface polysaccharides of capsulated pathogens, the level of vaccine-induced IgG antibodies and opsonophagocytosis were correlated. The finding that anti-␥DPGA mediates in vitro opsonophagocytosis and possibly protection against challenge with B. anthracis warrants clinical evaluation of ␥DPGA conjugates vaccines. Correlation coefficient between ELISA and reciprocal opsonophagocytic titer is 0.7, P ϭ 0.03.
